Abstract: A use of baicalin in preparation of a drug for treating a tumor irresponsive to immune checkpoint inhibitors (ICIs)/undergoing hyperprogression is provided, where the non-response to ICIs/hyperprogression of the tumor is caused by excessive Foxp3+Treg cells; the targeted tumor is one selected from the group consisting of melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), liver cancer, colorectal cancer (CRC), urothelial bladder cancer, and pancreatic cancer; and the ICIs is one or a mixture of two or more selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor. In the present disclosure, baicalin is used in combination with ICIs to inhibit a number of Foxp3+Treg cells in a tumor to play an anti-tumor sensitization effect, which can effectively treat a variety of tumors irresponsive to ICIs/undergoing hyperprogression caused by excessive Foxp3+Treg cells.

Abstract: A use of baicalin in preparation of a drug for treating a tumor irresponsive to immune checkpoint inhibitors (ICIs)/undergoing hyperprogression is provided, where the non-response to ICIs/hyperprogression of the tumor is caused by excessive Foxp3+Treg cells; the targeted tumor is one selected from the group consisting of melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), liver cancer, colorectal cancer (CRC), urothelial bladder cancer, and pancreatic cancer, and the ICIs is one or a mixture of two or more selected from the group consisting of a PD-1 inhibitor, a PD-L1 inhibitor, and a CTLA-4 inhibitor. In the present disclosure, baicalin is used in combination with ICIs to inhibit a number of Foxp3+Treg cells in a tumor to play an anti-tumor sensitization effect, which can effectively treat a variety of tumors irresponsive to ICIs/undergoing hyperprogression caused by excessive Foxp3+Treg cells.